<DOC>
	<DOCNO>NCT00698802</DOCNO>
	<brief_summary>This trial conduct Asia Africa . This trial aim comparison blood glucose control biphasic human insulin 100 IU/mL EX1000 .</brief_summary>
	<brief_title>Safety Efficacy Biphasic Human Insulin Compared EX1000 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 2 diabetes least 12 month Current biphasic human insulin ( BHI ) least 3 month monotherapy insulin combination OADs Body Mass Index ( BMI ) less equal 40.0 kg/m2 HbA1c le equal 9.5 % FPG ( SMPG ) less equal 12 mmol/L Treatment 1IU/kg insulin daily Treatment Glucagonlike peptide 1 mimetics dipeptityl peptidase IV inhibitor Known hypoglycaemia unawareness recurrent major hypoglycaemia , judge Investigator Known suspect allergy trial product relate product Receipt investigational drug within one month prior trial Any condition Investigator feel would interfere trial participation evaluation result , e.g . shiftworkers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>